Income statement, balance sheet and cash flow statement for the last 8 fiscal years, taken from the XBRL data BioNexus Gene Lab Corp files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2019
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
0.21
0.13
11.4
13.4
10.9
9.77
9.51
7.42
Cost of revenue
-0.18
0.07
9.67
11.1
9.67
8.44
8.22
6.34
Gross profit
0.03
0.06
1.72
2.27
1.26
1.33
1.29
1.09
Research and development
0.05
0.05
0.05
Selling and marketing
0.6
2.03
1.74
General and administrative
-0.24
0.36
1.33
1.28
1.73
2.44
1.83
1.54
Operating expenses
-4.41
4.94
4.48
Operating income
0.06
-0.28
1.27
1.06
-0.29
-2.59
-1.57
-2.97
Interest expense
0.01
0.01
Interest income
-0.01
0.07
0.15
0.08
Other non-operating income
-0.03
0.03
0.49
2.07
0.43
Pre-tax income
-0.28
1.26
1.04
-0.3
-2.61
-1.59
-2.98
Income tax
-0.03
0.02
-0.29
-0.05
-0.02
-0
0
Net income
0.03
-0.25
1.09
0.75
-0.36
-2.63
-1.6
-2.98
EBITDA
0.1
-0.23
1.36
1.15
-0.2
-2.51
-1.47
-2.85
EPS, basic
0.00
0.00
0.01
EPS, diluted
0.00
0.00
0.01
-0.17
-0.09
Shares, basic (weighted)
66.3
86.4
103
Shares, diluted (weighted)
66.3
86.4
103
15.9
17.8
Balance sheet
FY2019
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
1.26
0.86
2.79
2.12
2.12
4.52
2.89
2.38
Receivables
1.38
0.51
Inventory
0.02
0.01
1.18
1.52
0.98
1.14
1.39
0.68
Other current assets
0
0.08
Total current assets
1.3
0.88
7.99
7.15
6.02
8.05
7.43
5.45
Property, plant and equipment
0.34
0.31
1.79
1.63
1.51
1.51
1.52
1.6
Lease right-of-use assets
0.02
0.06
0.04
0.06
0.14
0.22
0.18
Total assets
1.65
1.23
10.1
9.57
8.74
11.4
10.4
9.25
Accounts payable
0
3.17
2.01
1.86
1.4
1.5
0
Accrued liabilities
0.17
0.13
Total current liabilities
0.06
0.05
3.37
2.33
2
1.63
1.95
0.52
Lease liabilities
0.01
0.04
0.02
0.04
0.1
0.16
0.12
Total liabilities
0.13
0.11
3.45
2.39
2.08
1.74
2.11
0.64
Paid-in capital
-5.01
-5.01
-5.01
-5.01
-5.01
-5.01
-5.01
-5.01
Retained earnings
-0.09
-0.33
0.76
1.51
1.16
-1.84
-3.44
-6.43
Other comprehensive income
-0.03
-0.02
0.13
-0.1
-0.41
-0.68
-0.56
-0.12
Shareholders' equity
1.52
1.12
6.66
7.18
6.67
9.66
8.32
8.61
Total equity
1.52
1.12
6.66
7.18
6.67
9.66
8.32
8.61
Total liabilities and equity
1.65
1.23
10.1
9.57
8.74
11.4
10.4
9.25
Shares outstanding
74.6
103
171
171
14.5
17.7
1.8
2.42
Cash flow statement
FY2019
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
0.03
-0.25
1.09
0.75
-0.36
2.63
-1.6
-2.98
Depreciation and amortization
0.04
0.04
0.09
0.09
0.09
0.08
0.1
0.11
Stock-based compensation
0.14
0.79
Deferred income tax
0
0
-0.03
-0
0.02
0.01
0
Change in inventory
-0.02
-0.01
-0.15
0.35
-0.54
0.16
-0.25
0.71
Cash from operations
-0.27
-0.22
0.55
0.01
0.55
-1.82
-2.09
-1.84
Capital expenditures
0.04
-0.01
-0.42
-0
0
-0.15
-0.23
-0.04
Cash from investing
-0.05
-0.01
1.32
-0.49
-0.45
-1.79
0.42
0.94
Debt repaid
0.02
Stock issued
0.74
-0.16
Cash from financing
0.74
-0.18
-0
-0.03
0.11
6.27
0
0.3
Exchange rate effect
-0.15
-0.21
-0.26
0.04
0.19
Net change in cash
-0.66
-0.01
2.4
-1.63
-0.4
Free cash flow
-0.23
-0.23
0.13
0.01
0.55
-1.97
-2.32
-1.88
Interest paid
-0
-0.01
0.01
0.01
0.01
0.01
0.01
0.01
Income taxes paid
-0.01
-0.14
-0.23
-0.17
-0.07
-0.04
-0.01
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $1.39 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Gross margin
12.3%
Gross profit / revenue.
Operating margin
-81.8%
Operating income / revenue.
EBITDA margin
-78.2%
EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin
-82.4%
Pre-tax income / revenue.
Net margin
-82.4%
Net income / revenue.
FCF margin
-27.3%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-27.1%
Cash from operations / revenue.
Return on equity (ROE)
-33.1%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-29.5%
Net income / average total assets.
Return on invested capital (ROIC)
-30.9%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
R&D / revenue
1.7%
Research and development expense / revenue.
Capex / revenue
0.2%
Capital expenditures / revenue.
D&A / revenue
3.6%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
-21.9%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
-12.1%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
-8.2%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Gross profit growth, 1y
-15.8%
Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 3y
-4.8%
Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Gross profit CAGR, 5y
-8.8%
Compound annual growth of gross profit over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Book value growth, 1y
3.5%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
8.9%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
5.3%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
-11.3%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
1.9%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
-1.8%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
6.08x
Current assets / current liabilities.
Quick ratio
1.54x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
1.52x
(Cash + short-term investments) / current liabilities.
Days inventory + days sales outstanding - days payables.
Per share
Metric
Value
How it is calculated
EPS, diluted
-$1.07
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$1.29
Revenue / diluted weighted shares.
FCF per share
-$0.35
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$0.35
Cash from operations / diluted weighted shares.
Book value per share
$3.22
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
1.30x
Market cap / revenue.
P/B
0.52x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
0.52x
Market cap / tangible book value, when positive.
EV/Sales
0.91x
Enterprise value / revenue.
FCF yield
-20.9%
Free cash flow / market cap.
Earnings yield
-63.2%
Net income / market cap (the inverse of P/E).
What was BioNexus Gene Lab Corp's revenue in fiscal 2025?
BioNexus Gene Lab Corp reported revenue of $7.4M for fiscal 2025, 21.9% lower than the year before.
Was BioNexus Gene Lab Corp profitable in fiscal 2025?
No. It reported a net loss of $3.0M.
How much free cash flow did BioNexus Gene Lab Corp generate in fiscal 2025?
Cash from operations of $1.8M minus capital expenditures of $37.0K left free cash flow of -$1.9M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.